Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma

Jennifer J.G. Welch, Cindy L. Schwartz, Meghan Higman, Lu Chen, Allen Buxton, Jennifer A. Kanakry, Samir B. Kahwash, Robert E. Hutchison, Debra L. Friedman, Richard F. Ambinder

Research output: Contribution to journalArticlepeer-review

Abstract

Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good surrogate for the presence of tumor DNA in children with Hodgkin lymphoma, as it is in adults, and whether it correlates with pediatric outcomes. Pediatric patients enrolled in a Children’s Oncology Group trial (AHOD0031) were studied at baseline and at 8 days after the initiation of treatment. At baseline, EBV DNA in cell-free blood correlated with the presence of EBV in tumor, and EBV DNA 8 days after the initiation of therapy predicted inferior event-free survival. EBV DNA in cell-free blood warrants further investigation as a marker of inadequate tumor response in Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00025259.

Original languageEnglish (US)
Pages (from-to)681-684
Number of pages4
JournalBlood Advances
Volume1
Issue number11
DOIs
StatePublished - Apr 25 2017

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this